Centene (CNC) traded lower as the market continued to discount the company’s 2026 earnings power after recent management commentary reaffirmed 2026 EPS targets but left investors focused on the durability of the turnaround. The setup remains sensitive because Centene is asking investors to underwrite a Marketplace profitability reset alongside stabilization in Medicaid medical cost ratios, and any hint of elevated acuity or rate mismatch can pressure the multiple. (investors.centene.com)

Centene’s latest public outlook frames 2026 as a rebuilding year, with adjusted diluted EPS guidance of greater than $3.00 and management pointing to actions taken to restore Marketplace profitability and stabilize Medicaid performance. Investors have been treating that guidance as vulnerable to downside if medical cost trends run hotter than pricing, especially in Medicaid where rate adequacy and acuity can shift quickly, and in Marketplace where risk adjustment dynamics have been a recurring pain point. (investors.centene.com)

An additional near-term headline has been Centene’s March 2026 Form 8-K describing a partial redemption of $1.0 billion of its 4.25% notes due 2027, with the redemption date set for March 25, 2026. While debt paydowns can be credit-positive, the market reaction has been more about whether free cash flow is being directed to the highest-return uses while operating performance remains under scrutiny. (stocktitan.net)

Traders will likely watch for incremental clarity on Medicaid trend vs. rate updates, any additional commentary on Marketplace pricing and risk adjustment expectations, and whether sell-side notes shift estimates or price targets as the year progresses. The next major catalyst is typically earnings and updated forward commentary, where investors will look for evidence that the 2026 run-rate is tracking to guidance rather than slipping back toward 2025-style volatility. (investors.centene.com)